Literature DB >> 24153115

TRIM5α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo.

Molly E Evans1, Chutima Kumkhaek1, Matthew M Hsieh1, Robert E Donahue2, John F Tisdale1, Naoya Uchida3.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) vectors can transduce human hematopoietic stem cells (HSC), but transduction efficiency varies among individuals. The innate immune factor tripartite motif-containing protein 5α (TRIM5α) plays an important role for restriction of retroviral infection. In this study, we examined whether TRIM5α could account for variations in transduction efficiency using both an established rhesus gene therapy model and human CD34(+) cell culture. Evaluation of TRIM5α genotypes (Mamu-1, -2, -3, -4, -5, and TrimCyp) in 16 rhesus macaques that were transplanted with transduced CD34(+) cells showed a significant correlation between TRIM5α Mamu-4 and high gene marking in both lymphocytes and granulocytes 6 months after transplantation. Since significant human TRIM5α coding polymorphisms were not known, we evaluated TRIM5α expression levels in human CD34(+) cells from 14 donors. Three days after HIV-1 vector transduction, measured transduction efficiency varied significantly among donors and was negatively correlated with TRIM5α expression levels. In summary, transduction efficiency in both rhesus and human CD34(+) cells was influenced by TRIM5α variations (genotypes and expression levels). Our findings are important for both understanding and mitigating the variability of transduction efficiency for rhesus and human CD34(+) cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24153115      PMCID: PMC3916046          DOI: 10.1038/mt.2013.256

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector.

Authors:  Naoya Uchida; Phillip W Hargrove; Coen J Lap; Molly E Evans; Oswald Phang; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Anh-Dao Nguyen; Matthew M Hsieh; Tyra G Wolfsberg; Robert E Donahue; Derek A Persons; John F Tisdale
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

3.  Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model.

Authors:  N Uchida; R P Weitzel; M E Evans; R Green; A C Bonifacino; A E Krouse; M E Metzger; M M Hsieh; R E Donahue; J F Tisdale
Journal:  Gene Ther       Date:  2013-11-21       Impact factor: 5.250

4.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

Authors:  C May; S Rivella; J Callegari; G Heller; K M Gaensler; L Luzzatto; M Sadelain
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

5.  Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.

Authors:  Naoya Uchida; Aylin Bonifacino; Allen E Krouse; Mark E Metzger; Gyorgy Csako; Agnes Lee-Stroka; Ross M Fasano; Susan F Leitman; Joseph J Mattapallil; Matthew M Hsieh; John F Tisdale; Robert E Donahue
Journal:  Exp Hematol       Date:  2011-04-15       Impact factor: 3.084

6.  Optimal conditions for lentiviral transduction of engrafting human CD34+ cells.

Authors:  N Uchida; M M Hsieh; J Hayakawa; C Madison; K N Washington; J F Tisdale
Journal:  Gene Ther       Date:  2011-05-05       Impact factor: 5.250

7.  Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.

Authors:  D A Persons; E R Allay; D E Sabatino; P Kelly; D M Bodine; A W Nienhuis
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Evolution of the antiretroviral restriction factor TRIMCyp in Old World primates.

Authors:  Elizabeth A Dietrich; Lisa Jones-Engel; Shiu-Lok Hu
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.

Authors:  Andrea Kirmaier; Fan Wu; Ruchi M Newman; Laura R Hall; Jennifer S Morgan; Shelby O'Connor; Preston A Marx; Mareike Meythaler; Simoy Goldstein; Alicia Buckler-White; Amitinder Kaur; Vanessa M Hirsch; Welkin E Johnson
Journal:  PLoS Biol       Date:  2010-08-24       Impact factor: 8.029

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  18 in total

1.  Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1-Based Lentiviral Vector.

Authors:  Huan He; Jing Xue; Weiming Wang; Lihong Liu; Chaobaihui Ye; Zhe Cong; Jason T Kimata; Chuan Qin; Paul Zhou
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

2.  Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.

Authors:  Naoya Uchida; Atsushi Fujita; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Hum Gene Ther Clin Dev       Date:  2017-04-17       Impact factor: 5.032

3.  Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.

Authors:  Denise Carbonaro Sarracino; Alice F Tarantal; C Chang I Lee; Michele Martinez; Xiangyang Jin; Xiaoyan Wang; Cinnamon L Hardee; Sabine Geiger; Christoph A Kahl; Donald B Kohn
Journal:  Mol Ther       Date:  2014-06-13       Impact factor: 11.454

4.  Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Authors:  Agne Taraseviciute; Victor Tkachev; Rafael Ponce; Cameron J Turtle; Jessica M Snyder; H Denny Liggitt; David Myerson; Luis Gonzalez-Cuyar; Audrey Baldessari; Chris English; Alison Yu; Hengqi Zheng; Scott N Furlan; Daniel J Hunt; Virginia Hoglund; Olivia Finney; Hannah Brakke; Bruce R Blazar; Carolina Berger; Stanley R Riddell; Rebecca Gardner; Leslie S Kean; Michael C Jensen
Journal:  Cancer Discov       Date:  2018-03-21       Impact factor: 39.397

5.  Kinetics of lentiviral vector transduction in human CD34(+) cells.

Authors:  Naoya Uchida; Rashidah Green; Josiah Ballantine; Luke P Skala; Matthew M Hsieh; John F Tisdale
Journal:  Exp Hematol       Date:  2015-10-21       Impact factor: 3.084

6.  BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.

Authors:  Selami Demirci; Jing Zeng; Yuxuan Wu; Naoya Uchida; Anne H Shen; Danilo Pellin; Jackson Gamer; Morgan Yapundich; Claire Drysdale; Jasmine Bonanno; Aylin C Bonifacino; Allen E Krouse; Nathaniel S Linde; Theresa Engels; Robert E Donahue; Juan J Haro-Mora; Alexis Leonard; Tina Nassehi; Kevin Luk; Shaina N Porter; Cicera R Lazzarotto; Shengdar Q Tsai; Mitchell J Weiss; Shondra M Pruett-Miller; Scot A Wolfe; Daniel E Bauer; John F Tisdale
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

7.  Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells.

Authors:  Carolina Petrillo; Daniela Cesana; Francesco Piras; Sara Bartolaccini; Luigi Naldini; Eugenio Montini; Anna Kajaste-Rudnitski
Journal:  Mol Ther       Date:  2014-10-01       Impact factor: 11.454

8.  Knockdown of TRIM5α or TRIM11 increases lentiviral vector transduction efficiency of human Muller cells.

Authors:  Monica M Sauter; Curtis R Brandt
Journal:  Exp Eye Res       Date:  2021-01-10       Impact factor: 3.467

Review 9.  Genome editing in large animal models.

Authors:  Lucy H Maynard; Olivier Humbert; Christopher W Peterson; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2021-10-01       Impact factor: 11.454

10.  Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies.

Authors:  Hans-Peter Kiem; Paritha I Arumugam; Christopher R Burtner; Catherine F Fox; Brian C Beard; Phillip Dexheimer; Jennifer E Adair; Punam Malik
Journal:  Mol Ther Methods Clin Dev       Date:  2014-12-17       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.